ArticleThe Lancet regional health. Europe2025
Health outcomes up to 3 years and post-exertional malaise in patients after hospitalization for COVID-19: a multicentre prospective cohort study (CO-FLOW).
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Muscle Abnormalities in Nonhospitalised Patients With Post-COVID-19 Condition.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Respiratory symptoms up to 18 months after COVID-19 - a longitudinal observational study.Respiratory research · 2026Observational
- Comorbidity Exposure-Window Definitions and Multidimensional Disparities in Long COVID Risk: Evidence from a U.S. National Cohort (2020-2024).medRxiv : the preprint server for health sciences · 2026Article
- Assessing Cognitive Deterioration After COVID-19 Infection (The ACDC Study): An Exploratory Multimodal Neuroimaging Study.Journal of clinical medicine · 2026Article
- Persistent health complications in COVID-19 hospitalized patients at tertiary care hospital in Western India.World journal of critical care medicine · 2026Article
- Persistent mitochondrial and endothelial dysfunction in non-hospitalized patients with Long COVID.Frontiers in medicine · 2026Article
- Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics.Journal of clinical immunology · 2025Article
- Trajectories of device-assessed physical activity and sleep in ICU- and non-ICU-treated patients up to 2 years after hospitalization for COVID-19, and their association with health-related quality of life.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Twelve-Month Health-Related Quality of Life Recovery Following COVID-19 Hospitalization: A Prospective Cohort Study from Lithuania.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many patients experience long-lasting health problems after COVID-19. The study aimed to assess 3-year trajectories of a comprehensive set of patient-reported outcome measures (PROMs) in patients hospitalized for COVID-19, particularly focusing on the 2- to 3-year trajectory. Additionally, we evaluated prevalence of post-exertional malaise (PEM) at 3 years, its risk factors, co-occurring health problems, and the 3-year trajectories of patients with and without PEM. Methods: The CO-FLOW multicentre prospective cohort study followed up adults hospitalized for COVID-19 in 7 hospitals, located in the Netherlands. Study assessments were performed at 3, 6, 12, 24, and 36 months post-discharge, conducted between July 1, 2020, and May 22, 2024. PROMs on recovery, symptoms, fatigue, mental health, cognition, participation, sleep quality, work status, health-related quality of life (HRQoL), and PEM were collected. Generalized estimating equations were used to assess health trajectories and multivariable logistic regression to identify risk factors for PEM. Findings: In total, 299/344 (87%) patients completed the 3-year follow-up and were included in the analysis. Complete recovery rates increased (p < 0.001), from 12% at 3 months to 24% at 3 years. Symptoms of impaired fitness, fatigue, and muscle weakness (all p < 0.0019) and PROMs for fatigue score, participation, return to work, and HRQoL (all p < 0.005) improved significantly over time, while PROMs for cognitive failures worsened (p < 0.001). Between the 2- and 3-year visits, memory problems (OR 1.4 [1.1-1.7], p < 0.001), and scores of fatigue (MD +1.0 [0.4-1.6], p = 0.002), cognitive failures (MD +2.2 [0.9-3.4], p < 0.001), and SF-36 mental component summary (-2.2 [-3.1 to -1.3], p < 0.001) significantly worsened. At 3 years, 66% of patients experienced fatigue, 63% impaired fitness, 59% memory problems, and 53% concentration problems. PROMs showed that 62% reported poor sleep quality, 55% fatigue, and 28% cognitive failures. PEM was reported by 105/292 (36%) patients at 3 years; risk factors were female sex (OR 3.4 [95% CI 1.9-6.0], p < 0.001), pre-existing pulmonary disease (3.0 [1.7-5.6], p < 0.001), physical inactivity pre-COVID-19 (2.3 [1.2-4.1], p = 0.008), and ICU treatment for COVID-19 (1.8 [1.02-3.0], p = 0.04). Concurrent fatigue, cognitive failures, and dyspnea were more common in patients with (42%) than without (6%) PEM. Patients with PEM showed poor health outcomes throughout the entire follow-up period, including worsening fatigue and HRQoL during the third year. Interpretation: Many health problems persisted up to 3 years post-discharge, with self-reported fatigue and cognitive problems worsening in the third year. PEM was common, and linked to a more severe phenotype of long COVID. These findings highlight the urgent need to optimize treatment options and investigate underlying pathological mechanisms of COVID-19. Funding: The Netherlands Organisation for Health Research and Development (ZonMw); Rijndam Rehabilitation; Laurens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.